Trial · NCT05054465
A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
NCT05054465, Phase 1, Phase 2, Unknown, Israeli Medical Association
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL. Trials, record NCT05054465. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05054465
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
- NCT number
- NCT05054465
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Israeli Medical Association
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Navitoclax, Venetoclax
- First posted
- 2021-09-23
- Last updated
- 2021-09-23
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free survival (EFS) | 2 years | EFS is defined for all patients and measured from the date of entry on study. It is measured until treatment failure defined as molecular or morphological relapse from CR, treatment discontinuation due to drug related toxicity or death from any cause, whichever occurs first. |
| Secondary | Overall survival (OS) | 2 years | |
| Secondary | Frequency of AE's during therapy | Recorded every 3 months for 2 years during follow up | AE's based on CTCAE 5.0 |
| Secondary | Rate of grade 3-4 GvHD events | 90 days | GvHD rate at 90 days - defined as Grade 3 or higher for aGvHD and moderate or severe for cGvHD as defined by the investigator following National Institutes of Health (NIH) criteria. |
| Secondary | Minimal Residual Disaease status | Recorded every 3 months for 2 years during follow up | Frequency of MRD negativity at the following time points: post induction II (week 12), after cycle 1 of-venetoclax and navitoclax therapy, after cycle 2 and before alloSCT and Q3 months post transplant (centrally assessed by PCR) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33593877 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05054465
GET https://conductscience.org/api/trials/v1/NCT05054465/registered